Reportlinker Adds Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology
NEW YORK, March 29, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology
Summary
GBI Research, the leading business intelligence provider, has released its latest research "Clinical Trial Endpoints in Oncology – Inclusion of Surrogate Endpoints and Shorter Endpoints will Ensure Faster Clinical Trials in Oncology", which essentially provides insights into clinical trial endpoints in oncology. The report details the endpoints and application of endpoints in oncological clinical trials. The report also analyzes the major four markets which include the colorectal cancer, prostate cancer, head and neck cancer and ovarian cancer therapeutics markets. It includes the analysis of endpoints of the major marketed products and their profiling. In addition to marketed products, the Phase III and Phase II clinical trials are also analyzed in terms of percentage cases. Analysis of prevailing and upcoming trends and their effects on the market and company profiling of major companies are included in the report.
Scope
The report details the endpoints and application of endpoints in Oncology Clinical Trials. The report covers -
- Data and analysis on the marketed products and analysis of endpoints used for the approval of the product.
- Analysis of the four major markets, which includes the colorectal cancer, prostate cancer, head and neck cancer and ovarian cancer therapeutics markets.
- Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Analysis of terminated trials is also included in this chapter. Only industry sponsored studies are included in the report.
- Trend Analysis analyzes prevailing and upcoming trends and their effects on the market.
- Company Profiling talks in detail about the companies which are strong in the market.
Reasons to buy
The report will help business development and marketing executives who are strategizing their product launches to -
- Build an effective R&D strategy by identifying the current state of endpoint achieved by the marketed products
- Identify the disease unmet needs for the four major cancers and align your pipeline product portfolio to tap the market potential.
- Improve our future market position by aligning your R&D pipeline to the areas with maximum success potential
- Improve your R&D efficiency by reducing research expenditure on unsuccessful endpoints
- Develop key strategic initiatives by understanding the key focus of leading companies with strong product pipeline.
Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Clinical Trials Endpoints In Oncology – Introduction 7
2.1 Introduction 7
2.2 GBI Research Report Guidance 8
3 Clinical Trials Endpoints In Oncology – Market Overview 9
3.1 Endpoints Used for Regular Approval 9
3.1.1 Survival 11
3.1.2 Progression-free survival 11
3.1.3 Tumor Response, Response Duration, and Time-to-Tumor Progression 12
3.1.4 DFS 12
4 Clinical Trials Endpoints in Oncology – Therapeutic Analysis 13
4.1 Colorectal Cancer 13
4.1.1 Major Marketed Drug Analysis 13
4.1.2 Profiling of Major Marketed Products 15
4.1.3 Phase III Molecules Analysis 22
4.1.4 Most Promising Drugs' Profiles 23
4.1.5 Phase II Molecules Analysis 29
4.1.6 Terminated Trials 35
4.2 Prostate Cancer 36
4.2.1 Major Marketed Drug Analysis 36
4.2.2 Profiling of Major Marketed Products 38
4.2.3 Phase III Molecules Analysis 50
4.2.4 Most Promising Drugs' Profiles 51
4.2.5 Phase II Molecules Analysis 58
4.2.6 Terminated Trials 63
4.3 Head and Neck Cancer Therapeutics 63
4.3.1 Major Marketed Drug Analysis 63
4.3.2 Profiling of Major Marketed Products 65
4.3.3 Phase III Molecules Analysis 68
4.3.4 Phase II molecules Analysis 73
4.3.5 Terminated Trials 76
4.4 Ovarian Cancer 77
4.4.1 Major Marketed Drug Analysis 77
4.4.2 Profiling of Major Marketed Products 78
4.4.3 Phase III molecules Analysis 81
4.4.4 Phase II Molecules Analysis 89
4.4.5 Terminated Trials 93
5 Clinical Trials Endpoints In Oncology – New Trends and Technologies 94
5.1 Microsatellite Instability (MSI) as a Diagnostic Tool in Colorectal Cancer 94
5.2 New Biomarker for Aggressive Prostate Cancer 94
6 Clinical Trials Endpoints In Oncology – Company Profiling 95
6.1 F. Hoffmann La Roche 95
6.1.1 Business Description 95
6.1.2 Financial Overview 95
6.1.3 Major Oncology Products 96
6.2 Bristol-Myers Squibb 98
6.2.1 Business Description 98
6.2.2 Financial Overview 98
6.2.3 Major Oncology Products 98
6.3 Sanofi-Aventis 100
6.3.1 Business Description 100
6.3.2 Financial Overview 100
6.3.3 Major Oncology Products 101
6.4 Merck KGaA 103
6.4.1 Business Description 103
6.4.2 Financial Overview 104
6.4.3 Major Oncology Products 104
6.5 Pfizer Inc. 105
6.5.1 Business Description 105
6.5.2 Financial Overview 106
6.5.3 Major Oncology Products 106
6.6 AstraZeneca 107
6.6.1 Business Description 107
6.6.2 Financial Overview 108
6.6.3 Major Oncology Products 109
6.7 Takeda Pharmaceuticals 111
6.7.1 Business Description 111
6.7.2 Financial Overview 111
6.7.3 Major Oncology Products 111
6.8 GlaxoSmithKline plc. 113
6.8.1 Business Description 113
6.8.2 Financial Overview 113
6.8.3 Major Oncology Products 114
7 Clinical Trials Endpoints In Oncology – Appendix 115
7.1 Market Definitions 115
7.2 Abbreviations 115
7.3 Research Methodology 118
7.3.1 Coverage 118
7.3.2 Secondary Research 118
7.3.3 Primary Research 119
7.3.4 Expert Panel Validation 119
7.4 Contact Us 119
7.5 Disclaimer 120
7.6 Sources 120
List of Tables
1.1 List of Tables
Table 1: Endpoints for Approval of Oncology Drug Marketing Applications, Global, 1990-2010 9
Table 2: Colorectal Cancer Therapeutics Market – Approved Products, Global, 1990-2010 13
Table 3: Colorectal Cancer Therapeutics Market, Global, Efficacy, 2010 14
Table 4: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010 20
Table 5: Colorectal Cancer Therapeutics Market, Phase III Molecules , Global, 2010 25
Table 6: Colorectal Cancer Therapeutics Market, Phase II Molecules , Global, 2010 30
Table 7: Discontinued Drugs for Colorectal Cancer, Global, 2010 35
Table 8: Prostate Cancer Therapeutics Market- Approved Products, Global, 1990-2010 36
Table 9: Prostate Cancer Therapeutics Market, Global, Efficacy, Global, 2010 37
Table 10: Prostate Cancer Therapeutics Market, Phase III Molecules , Global, 2010 55
Table 11: Prostate Cancer Therapeutics Market, Phase II Molecules, Global, 2010 59
Table 12: Discontinued Drugs for Prostate Cancer, Global, 2010 63
Table 13: Head and Neck Cancer Therapeutics Market – Approved Products, Global, 1990-2010 63
Table 14: Head and Neck Cancer Therapeutics Market, Global, Efficacy, 2010 64
Table 15: Head and Neck Cancer Therapeutics Market, Phase III Molecules ,Global, 2010 71
Table 16: Head and Neck Cancer Therapeutics Market, Phase II Molecules , Global, 2010 74
Table 17: Discontinued Drugs for Head and Neck Cancer, Global, 2010 76
Table 18: Ovarian Cancer Therapeutics Market- Approved Products, Global, 1990-2010 77
Table 19: Ovarian Cancer Therapeutics Market, Global, Efficacy, 2010 77
Table 20: Ovarian Cancer Therapeutics Market, Phase III Molecules , Global, 2010 87
Table 21: Ovarian Cancer Therapeutics Market, Phase II Molecules , Global, 2010 90
Table 22: Discontinued Drugs for Ovarian Cancer, Global, 2010 93
Table 23: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010 102
List of Figures
1.2 List of Figures
Figure 1: Colorectal Cancer Therapeutics Market – Clinical Pipeline Phase III by Primary Endpoints, 2010 22
Figure 2: Colorectal Cancer Therapeutics Market – Clinical Pipeline Phase II by Primary Endpoints, 2010 29
Figure 3: Prostate Cancer Therapeutics Market – Clinical Pipeline Phase III by Primary Endpoints, 2010 50
Figure 4: Prostate Cancer Therapeutics Market – Clinical Pipeline Phase II by Primary Endpoints, 2010 58
Figure 5: Head and Neck Cancer Therapeutics Market – Clinical Pipeline Phase III by Primary Endpoints, 2010 68
Figure 6: Head and Neck Cancer Therapeutics Market – Clinical Pipeline Phase III by Primary Endpoints, 2010 73
Figure 7: Ovarian Cancer Therapeutics Market – Clinical Pipeline Phase III by Primary Endpoints, 2010 81
Figure 8: Ovarian Cancer Therapeutics Market – Clinical Pipeline Phase II by Primary Endpoints, 2010 89
To order this report:
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article